2020
Managing rheumatic diseases during COVID-19
Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clinical Rheumatology 2020, 39: 3245-3254. PMID: 32895747, PMCID: PMC7476772, DOI: 10.1007/s10067-020-05387-8.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesRheumatic diseasesImmunosuppressive agentsRheumatology practiceCOVID-19Multisystem autoimmune rheumatic diseaseLong-term complicationsCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionDisease 2019 pandemicMode of spreadImmunosuppressant managementImmunosuppressant medicationsViral illnessOrgan failureClinical featuresAutoimmune diseasesSerious infectionsTreatment optionsEffective vaccineImmune systemMedicationsDiseasePatients
2017
Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus
Kumthekar A, Danve A, Deodhar A. Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus. The Journal Of Rheumatology 2017, 44: 1416-1417. PMID: 28864669, DOI: 10.3899/jrheum.170327.Peer-Reviewed Original Research
2014
Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus—A case report
Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus—A case report. Seminars In Arthritis And Rheumatism 2014, 44: 195-197. PMID: 25005336, DOI: 10.1016/j.semarthrit.2014.05.006.Peer-Reviewed Original ResearchConceptsActive systemic lupus erythematosusSystemic lupus erythematosusUse of belimumabCase reportLupus erythematosusPresence of SLEMild Ebstein's anomalyFirst case reportBelimumab usePregnancy RegistryActive lupusUnacceptable toxicityEbstein's anomalyUneventful coursePoor outcomeCaucasian womenBelimumabPregnancyModerate dosesMycophenolateErythematosusReportRelevant literatureAzathioprinePrednisone